| 产品详情 |
| Edit |   |
|---|
| Product Name | Sotagliflozin |
|---|
| Description | Purity >98%. Inhibiting renal glucose reabsorption through the sodium-glucose cotransporter (SGLT) offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes. While the majority of glucose is reabsorbed from glomerular filtrate by SGLT2, which is predominantly expressed in the kidney S1 segment of the proximal tubule, SGLT1 reabsorbs glucose in the distal S3 segment of the renal proximal tubule as well as from the small intestine. Sotagliflozin is an orally available L-xyloside that potently inhibits both SGLT1 and SGLT2 (IC50 s = 36 and 1.8 nM, respectively, for human isoforms in vitro ). It improves glycemic control in nonobese diabetes prone mice with type 1 diabetes and in patients with type 2 diabetes in a randomized, placebo-controlled clinical trial. Sotagliflozin also increases serum glucagon-like peptide 1 and peptide YY levels by reducing SGLT1-mediated absorption of intestinal glucose. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | methyl 5S-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-Beta-L-xylopyranoside, LP 802034, LX4211 |
|---|
| Gene, Accession, CAS # | CAS: 1018899-04-1 |
|---|
| Catalog # | LS-H9972 |
|---|
| Price | |
|---|
| Order / More Info | Sotagliflozin from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|